Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study with Mass General

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its collaborative multiple sclerosis imaging study with Massachusetts General Hospital, the company announced Tuesday. Preliminary imaging data from the study show an encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, according to the company.

The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, the process of myelin degradation that underlies multiple sclerosis. Quantum BioPharma believes this technique could enhance the development of MS therapies, including its investigational candidate Lucid-MS. The company submitted an Investigational New Drug application for a Phase 2 trial of Lucid-MS to the U.S. Food and Drug Administration in March 2026.

The milestone comes as Quantum BioPharma continues to focus on building a portfolio of assets for neurodegenerative and metabolic disorders. The full press release is available at https://ibn.fm/4IZ0y.

Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is developing Lucid-MS, a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. The company also holds a 19.84% stake in Unbuzzd Wellness Inc., which markets the OTC hangover remedy UNBUZZD, and is entitled to royalty payments from its sales.

The implications of this study are significant. If the PET imaging technique proves effective, it could provide a direct way to visualize demyelination in living patients, enabling earlier diagnosis and more precise monitoring of disease progression. This would be a major advance over current imaging methods, which are indirect and often miss gray matter lesions. For Quantum BioPharma, success of the imaging study could also accelerate the development of Lucid-MS by providing a biomarker to measure the drug’s effect on myelin repair.

Dr. Zeeshan Latif, CEO of Quantum BioPharma, stated in the release that the midpoint enrollment milestone is a testament to the collaboration with Massachusetts General Hospital and the dedication of the clinical team. He emphasized that the preliminary imaging data are encouraging and support the potential of the [¹⁸F]3F4AP tracer to detect demyelination.

Multiple sclerosis affects approximately 2.8 million people worldwide, and current therapies primarily target inflammation rather than directly promoting myelin repair. A PET tracer that can visualize myelin damage could transform how the disease is studied and treated.

For more information about Quantum BioPharma and its pipeline, visit the company’s newsroom at https://ibn.fm/QNTM.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study with Mass General.

The post Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study with Mass General appeared first on citybuzz.